We are excited to have presented data at the #RareDiseaseDay2024 Symposium, CDG Scientific and Family Conference showing encouraging efficacy from our ongoing #clinicaltrial of GLM101 in #PMM2CDG. Read the press release here: https://lnkd.in/gJuXvR79 #CDGresearch #rarediseases #raredisease #clinicaltrials #RareDiseaseDay
Glycomine Inc.
Biotechnology Research
San Carlos, California 1,460 followers
We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
About us
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
- Website
-
http://glycomine.com/
External link for Glycomine Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Carlos, California
- Type
- Privately Held
Locations
-
Primary
Get directions
733 Industrial Rd
San Carlos, California 94070, US
Employees at Glycomine Inc.
Updates
-
We are excited to announce that the first pediatric patient has been dosed in a Phase 2 clinical study of GLM101, which is in development as the first potential disease-modifying treatment for #PMM2CDG. https://lnkd.in/gtZhSd2W #CDGresearch #rarediseases #raredisease #clinicaltrial #clinicaltrials #glycosylation #glycoprotein #glycans #glycosylated #glycoresearch
-
-
We are excited to have presented data at #ASHG23 from our ongoing natural history study, providing insights into genetic mutations and biomarkers for #PMM2CDG. The data will help design future interventional studies for GLM101, our lead candidate GLM101 currently in Phase 2 #clinicaltrials. Read the press release and download the poster here: https://lnkd.in/ggZyzuss #PMM2CDG #CDGresearch #rarediseases #raredisease #clinicaltrial #glycosylation #glycoprotein #glycans #glycosylated #glycoresearch
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG | Glycomine
glycomine.com
-
We are looking for an Accounts Payable & Administrative Support Specialist! Learn more at: https://smrtr.io/g-57G #biotech #careers #joinus #jobopening #hiring #nowhiring #job #opening #biotechjobs
-
-
We're proud to introduce Dr. Rose Marino as our Chief Medical Officer. With more than 20 years of combined experience in pediatric endocrinology and clinical research, she joins us at a crucial phase in our mission to develop GLM101, a potential game-changer for #PMM2CDG. Welcome, Dr. Marino! https://lnkd.in/gUvt3RuC
Glycomine Appoints Dr. Rose Marino Chief Medical Officer | Glycomine
glycomine.com